Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Retrospective genotype-phenotype analysis in a 305 patient cohort referred for testing of a targeted epilepsy panel.

Hesse AN, Bevilacqua J, Shankar K, Reddi HV.

Epilepsy Res. 2018 May 16;144:53-61. doi: 10.1016/j.eplepsyres.2018.05.004. [Epub ahead of print]

PMID:
29778030
2.

Genomic Profiling of Two Histologically Distinct Rare Urothelial Cancers in a Clinical Setting to Identify Potential Therapeutic Options for Treatment and Management of Disease.

Hesse AN, Fabricius W, Thomas CA, Gaindh R, Christman R, Selvam P, Prego M, Lewis G, Uvalic J, Bergeron D, Burns S, Sisson B, Kelly K, Rueter J, Reddi HV.

Case Rep Oncol. 2018 Mar 27;11(1):196-205. doi: 10.1159/000487882. eCollection 2018 Jan-Apr.

3.

Clinical utility of a 377 gene custom next-generation sequencing epilepsy panel.

Bevilacqua J, Hesse A, Cormier B, Davey J, Patel D, Shankar K, Reddi HV.

J Genet. 2017 Sep;96(4):681-685.

4.

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB.

Lung Cancer. 2017 Apr;106:17-21. doi: 10.1016/j.lungcan.2017.01.011. Epub 2017 Jan 25.

5.

The first patient with tandem duplication of 6q14q16: Molecular and phenotypic characterization.

Sanmann JN, Casas KA, Bevilacqua J, Bishay DL, Clark T, Van Dyke AZ, Leiferman PC, Reddi HV, Starr LJ.

Am J Med Genet A. 2016 Sep;170(9):2416-20. doi: 10.1002/ajmg.a.37797. Epub 2016 Jun 23. Review.

PMID:
27338032
6.

A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis.

Liu YC, Reddi HV, Waheed S, Alapat D, Highsmith WE, Edmondson RD, Barlogie B, van Rhee F.

Amyloid. 2014 Jun;21(2):134-5. doi: 10.3109/13506129.2014.883373. Epub 2014 Feb 11. No abstract available.

PMID:
24517438
7.

Discordant results between biochemical and molecular transthyretin assays: lessons learned from a unique testing algorithm at the Mayo Clinic.

Reddi HV, Thomas BC, Willkomm KS, Ferber MJ, Rumilla KM, Raymond KM, O'Brien JF, Highsmith WE.

J Genet. 2013 Dec;92(3):599-604. No abstract available.

8.

RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Smallridge RC, Chindris AM, Asmann YW, Casler JD, Serie DJ, Reddi HV, Cradic KW, Rivera M, Grebe SK, Necela BM, Eberhardt NL, Carr JM, McIver B, Copland JA, Thompson EA.

J Clin Endocrinol Metab. 2014 Feb;99(2):E338-47. doi: 10.1210/jc.2013-2792. Epub 2013 Dec 2.

9.

Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life.

Reddi HV, Jenkins S, Theis J, Thomas BC, Connors LH, Van Rhee F, Highsmith WE Jr.

J Mol Diagn. 2014 Jan;16(1):68-74. doi: 10.1016/j.jmoldx.2013.08.001. Epub 2013 Oct 30.

PMID:
24184229
10.

Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy.

Reddi HV, Driscoll CB, Madde P, Milosevic D, Hurley RM, McDonough SJ, Hallanger-Johnson J, McIver B, Eberhardt NL.

Cancer Gene Ther. 2013 May;20(5):267-75. doi: 10.1038/cgt.2013.16. Epub 2013 Apr 19.

PMID:
23598436
11.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

J Oncol Pract. 2012 May;8(3 Suppl):e1s-5s. doi: 10.1200/JOP.2011.000496.

12.

Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.

Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC 3rd, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL.

Cancer Gene Ther. 2012 Sep;19(9):659-65. doi: 10.1038/cgt.2012.47. Epub 2012 Jul 13.

PMID:
22790962
13.

Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies.

Marlow LA, von Roemeling CA, Cooper SJ, Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV, Tun HW, Döppler HR, Storz P, Smallridge RC, Copland JA.

J Cell Sci. 2012 Sep 15;125(Pt 18):4253-63. doi: 10.1242/jcs.097428. Epub 2012 Jun 20.

14.

Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models.

Reddi HV, Madde P, Cohen YC, Bangio L, Breitbart E, Harats D, Bible KC, Eberhardt NL.

Genes Cancer. 2011 Oct;2(10):993-5. doi: 10.1177/1947601912437933.

15.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

Am J Manag Care. 2012 May 1;18(5):e162-7.

16.

The Putative PAX8/PPARγ Fusion Oncoprotein Exhibits Partial Tumor Suppressor Activity through Up-Regulation of Micro-RNA-122 and Dominant-Negative PPARγ Activity.

Reddi HV, Madde P, Milosevic D, Hackbarth JS, Algeciras-Schimnich A, McIver B, Grebe SK, Eberhardt NL.

Genes Cancer. 2011 Jan;2(1):46-55. doi: 10.1177/1947601911405045.

17.

Analysis of circulating microRNA: preanalytical and analytical challenges.

McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A.

Clin Chem. 2011 Jun;57(6):833-40. doi: 10.1373/clinchem.2010.157198. Epub 2011 Apr 12.

18.

Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction.

Rostambeigi N, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV, Madde P, Zhang S, Asmann YW, Anderson JM, Schimke JM, Nair KS, Eberhardt NL, Kudva YC.

Transplantation. 2011 Mar 27;91(6):615-23. doi: 10.1097/TP.0b013e3182094a33.

19.

Expression of the PAX8/PPARγ Fusion Protein Is Associated with Decreased Neovascularization In Vivo: Impact on Tumorigenesis and Disease Prognosis.

Reddi HV, Madde P, Marlow LA, Copland JA, McIver B, Grebe SK, Eberhardt NL.

Genes Cancer. 2010 May;1(5):480-492.

20.

Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis.

Algeciras-Schimnich A, Milosevic D, McIver B, Flynn H, Reddi HV, Eberhardt NL, Grebe SK.

Clin Chem. 2010 Mar;56(3):391-8. doi: 10.1373/clinchem.2009.134015. Epub 2010 Jan 7.

21.

The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.

Eberhardt NL, Grebe SK, McIver B, Reddi HV.

Mol Cell Endocrinol. 2010 May 28;321(1):50-6. doi: 10.1016/j.mce.2009.10.013. Epub 2009 Oct 31. Review.

22.

The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer.

Placzkowski KA, Reddi HV, Grebe SK, Eberhardt NL, McIver B.

PPAR Res. 2008;2008:672829. doi: 10.1155/2008/672829. Epub 2008 Oct 29.

23.

ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice.

Reddi HV, Madde P, Reichert-Eberhardt AJ, Galanis EC, Copland JA, McIver B, Grebe SK, Eberhardt NL.

Cancer Gene Ther. 2008 Nov;15(11):750-7. doi: 10.1038/cgt.2008.44. Epub 2008 Jun 27.

24.

The notch regulator MAML1 interacts with p53 and functions as a coactivator.

Zhao Y, Katzman RB, Delmolino LM, Bhat I, Zhang Y, Gurumurthy CB, Germaniuk-Kurowska A, Reddi HV, Solomon A, Zeng MS, Kung A, Ma H, Gao Q, Dimri G, Stanculescu A, Miele L, Wu L, Griffin JD, Wazer DE, Band H, Band V.

J Biol Chem. 2007 Apr 20;282(16):11969-81. Epub 2007 Feb 22.

25.

The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis.

Reddi HV, McIver B, Grebe SK, Eberhardt NL.

Endocrinology. 2007 Mar;148(3):932-5. Epub 2006 Aug 31. Review.

PMID:
16946003
26.
27.

Heparan sulfate-independent infection attenuates high-neurovirulence GDVII virus-induced encephalitis.

Reddi HV, Kumar AS, Kung AY, Kallio PD, Schlitt BP, Lipton HL.

J Virol. 2004 Aug;78(16):8909-16.

28.

Virus persistence in an animal model of multiple sclerosis requires virion attachment to sialic acid coreceptors.

Kumar AS, Reddi HV, Kung AY, Dal Canto M, Lipton HL.

J Virol. 2004 Aug;78(16):8860-7.

29.

Susceptibility of peritoneal macrophages to infection by Theiler's virus.

Jelachich ML, Reddi HV, Trottier MD, Schlitt BP, Lipton HL.

Virus Res. 2004 Sep 1;104(2):123-7.

PMID:
15246649
30.

Self-association of the hepatitis B virus X protein in the yeast two-hybrid system.

Reddi HV, Kumar V.

Biochem Biophys Res Commun. 2004 May 14;317(4):1017-22.

PMID:
15094370
32.

Heparan sulfate mediates infection of high-neurovirulence Theiler's viruses.

Reddi HV, Lipton HL.

J Virol. 2002 Aug;76(16):8400-7. Erratum in: J Virol. 2003 Aug;77(16):9106.

Supplemental Content

Loading ...
Support Center